Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
Polyrizon (Nasdaq: PLRZ), a development stage biotech company focused on innovative intranasal hydrogels, has appointed Asaf Azulay as Vice President of Regulatory Affairs and Quality Assurance (RA/QA). Azulay, currently Managing Director of Eurofins' Li-Med team, brings over 20 years of experience in the medical devices industry.
The appointment aligns with Polyrizon's commitment to maintaining high industry standards while advancing its product pipeline. CEO Tomer Izraeli emphasized that Azulay's expertise will be important in navigating complex regulatory environments and advancing the company's product portfolio. The role aims to ensure innovation progress while maintaining patient safety as regulations become more stringent.
Polyrizon (Nasdaq: PLRZ), un'azienda biotech in fase di sviluppo focalizzata su idrogeli intranasali innovativi, ha nominato Asaf Azulay come Vice Presidente per le Affari Regolatori e la Qualità (RA/QA). Azulay, attualmente Direttore Generale del team Li-Med di Eurofins, porta con sé oltre 20 anni di esperienza nel settore dei dispositivi medici.
La nomina è in linea con l'impegno di Polyrizon a mantenere alti standard del settore, mentre prosegue nella sua pipeline di prodotti. Il CEO Tomer Izraeli ha sottolineato che l'expertise di Azulay sarà fondamentale per affrontare ambienti regolatori complessi e per far avanzare il portafoglio prodotti dell'azienda. Il ruolo mira a garantire il progresso nell'innovazione, mantenendo nel contempo la sicurezza dei pazienti, poiché le normative diventano sempre più rigorose.
Polyrizon (Nasdaq: PLRZ), una compañía biotecnológica en etapa de desarrollo centrada en hidrogeles intranasales innovadores, ha nombrado a Asaf Azulay como Vicepresidente de Asuntos Regulatorios y Aseguramiento de Calidad (RA/QA). Azulay, actualmente Director General del equipo Li-Med de Eurofins, aporta más de 20 años de experiencia en la industria de dispositivos médicos.
El nombramiento se alinea con el compromiso de Polyrizon de mantener altos estándares de la industria mientras avanza en su cartera de productos. El CEO Tomer Izraeli enfatizó que la experiencia de Azulay será importante para navegar en entornos regulatorios complejos y avanzar en el portafolio de productos de la empresa. El papel tiene como objetivo asegurar el progreso de la innovación mientras se mantiene la seguridad del paciente, a medida que las regulaciones se vuelven más estrictas.
폴리라이존 (Nasdaq: PLRZ)은 혁신적인 비강 하이드로겔에 중점을 둔 개발 단계의 생명공학 회사로, 아사프 아줄라이를 규제 업무 및 품질 보증 부사장(RA/QA)으로 임명했습니다. 현재 유로핀의 Li-Med 팀 총괄 이사인 아줄라이는 의료 기기 산업에서 20년 이상의 경험을 보유하고 있습니다.
이번 임명은 폴리라이존이 높은 산업 표준을 유지하면서 제품 파이프라인을 발전시키려는 의지에 부합합니다. CEO인 토머 이즈라엘리는 아줄라이의 전문성이 복잡한 규제 환경을 탐색하고 회사의 제품 포트폴리오를 발전시키는 데 중요하다고 강조했습니다. 이 역할은 규제가 더욱 엄격해짐에 따라 혁신의 진행과 환자 안전을 유지하는 것을 목표로 합니다.
Polyrizon (Nasdaq: PLRZ), une entreprise biotech en phase de développement spécialisée dans les hydrogel intranasaux innovants, a nommé Asaf Azulay au poste de Vice-Président des Affaires Réglementaires et de l'Assurance Qualité (RA/QA). Actuellement Directeur Général de l'équipe Li-Med d'Eurofins, Azulay possède plus de 20 ans d'expérience dans l'industrie des dispositifs médicaux.
Cette nomination s'inscrit dans l'engagement de Polyrizon à maintenir de hauts standards de l'industrie tout en faisant progresser son portefeuille de produits. Le PDG Tomer Izraeli a souligné que l'expertise d'Azulay sera essentielle pour naviguer dans des environnements réglementaires complexes et faire avancer le portefeuille de produits de l'entreprise. Le rôle vise à garantir le progrès de l'innovation tout en préservant la sécurité des patients, à mesure que les réglementations deviennent plus strictes.
Polyrizon (Nasdaq: PLRZ), ein Biotech-Unternehmen in der Entwicklungsphase, das sich auf innovative intranasale Hydrogele konzentriert, hat Asaf Azulay zum Vizepräsidenten für Regulatory Affairs und Qualitätsmanagement (RA/QA) ernannt. Azulay, der derzeit Geschäftsführer des Li-Med-Teams von Eurofins ist, bringt mehr als 20 Jahre Erfahrung in der Medizintechnik mit.
Die Ernennung entspricht Polyrizons Engagement für die Aufrechterhaltung hoher Branchenstandards, während das Produktportfolio weiterentwickelt wird. CEO Tomer Izraeli betonte, dass Azulays Fachwissen wichtig sein wird, um komplexe regulatorische Umgebungen zu navigieren und das Produktportfolio des Unternehmens voranzutreiben. Das Ziel dieser Rolle ist es, den Fortschritt der Innovation sicherzustellen und gleichzeitig die Patientensicherheit zu gewährleisten, während die Vorschriften strenger werden.
- Strategic appointment of experienced RA/QA executive with 20+ years in medical devices industry
- Enhanced regulatory compliance capabilities to support product development pipeline
- Strengthened leadership team with expertise in global regulatory landscape
- None.
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins’ Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon’s ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions.
Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and implementing regulatory strategies. His deep understanding of the global regulatory landscape will play a vital role in ensuring Polyrizon’s compliance with international standards and achieving its strategic goals.
As regulations tighten, the role of the RA/QA leader is more crucial than ever. The new role aims to ensure that the Company’s innovation does not hit roadblocks and that patient safety is a key component.
"We are excited to strengthen our team with proven expertise in RA/QA to support Polyrizon’s mission of delivering safe and effective solutions to market,” said Tomer Izraeli, CEO of Polyrizon. “Asaf’s extensive experience and insights will be instrumental in navigating complex regulatory environments and advancing our product portfolio."
The engagement further positions Polyrizon to navigate the regulatory landscape efficiently, enhancing its ability to bring breakthrough therapies to patients worldwide.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions, how the appointment of the QA/RA leader aims to ensure that the Company’s innovation does not hit roadblocks and its mission of delivering safe and effective solutions to market. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s prospectus (Registration No. 333-266745), dated October 24, 2024 and filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
Who is the new VP of Regulatory Affairs at Polyrizon (PLRZ)?
What experience does Polyrizon's (PLRZ) new RA/QA VP bring to the role?
How will the new RA/QA VP appointment impact Polyrizon's (PLRZ) product development?
What is the strategic significance of PLRZ's new RA/QA VP appointment?
